# US 2016/0250407 A1 · Modular Extracorporeal Systems and Methods for Treating Blood-Borne Diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250407 A1
- Document ID: US20160250407A1
- Status: Published application
- Kind: A1
- Application number: 14/953,486
- Filed: 2015-11-30
- Published: 2016-09-01
- Earliest claimed: 2011-01-07
- Assignees: Somerset Group Enterprises, Inc.
- Applicants: Somerset Group Enterprises, Inc.
- Inventors: David G. Greenberg; Scott Puritz; Tatiana Koutchma; Juan N. Walterspiel
- Web page: https://patentgrep.com/patent/US20160250407A1

## CPC

- A61M 1/3672: {Means preventing coagulation}
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61M 1/14: Dialysis systems; Artificial kidneys; Blood oxygenators (semi-permeable membranes characterised by the material, manufacturing processes therefor B01D71/00){; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis}
- A61M 1/16: with membranes
- A61M 1/3472: {with treatment of the filtrate}
- A61M 1/3486: {Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents}
- A61M 1/36: Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation {; Extra-corporeal blood circuits}
- A61M 1/3609: {Physical characteristics of the blood, e.g. haematocrit, urea}
- A61M 1/3621: {Extra-corporeal blood circuits (single-needle circuits A61M1/30)}
- A61M 1/3678: {Separation of cells using wave pressure; Manipulation of individual corpuscles}
- A61M 1/3681: {by irradiation}
- A61M 1/3683: {using photoactive agents}
- A61M 1/3686: {by removing photoactive agents after irradiation}
- A61M 1/3687: {Chemical treatment (A61M1/3675 takes precedence)}
- A61M 1/369: {Temperature treatment}
- A61M 1/3693: {using separation based on different densities of components, e.g. centrifuging}
- A61N 5/00: Radiation therapy (ultrasound therapy A61N7/00; devices or apparatus applicable to both therapy and diagnosis A61B6/00)
- A61P 19/00: Drugs for skeletal disorders
- A61P 31/04: Antibacterial agents
- G01N 33/5091: {for testing the pathological state of an organism}
- A61M 1/1698: {Blood oxygenators with or without heat-exchangers (intracorporal A61M1/1678; manufacturing of membranes therefor B01D67/00; semi-permeable membranes for separation processes characterised by their properties B01D69/00; semi-permeable membranes characterised by their material B01D71/00)}
- A61M 1/32: Oxygenators without membranes
- A61M 1/3633: {Blood component filters, e.g. leukocyte filters}
- A61M 2202/0208: Oxygen
- A61M 2202/0225: Carbon oxides, e.g. Carbon dioxide
- A61M 2202/0233: Carbon monoxide
- A61M 2202/025: Helium
- A61M 2202/0258: Krypton (KR)
- A61M 2202/0266: Nitrogen (N)
- A61M 2202/0275: Nitric oxide [NO]
- A61M 2202/0291: Xenon
- A61M 2202/20: Pathogenic agents
- A61M 2205/05: combined with other kinds of therapy
- A61M 2205/053: ultraviolet
- A61M 2205/75: with filters
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Extracorporeal systems and methods for treating blood-borne diseases in a subject or for developing drugs to treat blood-borne diseases include various environmental and treatment modules that can be tailored to a specific disease or infection. In certain embodiments of the systems and methods, a blood sample is treated with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, sonification, radiation, or a combination thereof, under environmental conditions that are effective for the treatment.

## Claims

### Claim at position 1

-4. (canceled)

### Claim 5

An extracorporeal method for treating a blood-borne disease comprising the steps of:
a) removing blood from a subject;
b) contacting the blood with an anticoagulant;
c) optionally separating the blood into two or more blood fractions;
d) modifying the environment of the blood or a blood fraction;
e) treating the blood or blood fraction with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, centrifugation, microwave, radiation, sonification, or a combination thereof; and
f) returning at least a portion of the blood or blood fraction to the subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein the anticoagulant is heparin or sodium citrate.

### Claim 7 (depends on 5)

The method of claim 5, wherein the blood is separated into a red blood cell fraction, a buffy coat fraction, a platelet fraction, a plasma fraction, or a combination thereof.

### Claim 8 (depends on 5)

The method of claim 5, wherein the step of modifying the environment of the blood or a blood fraction comprises at least one of modifying the pH, modifying the temperature, modifying the oxygenation, modifying the available nutrients, modifying the carbon dioxide, modifying the osmolality, or a combination thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the modifying the environment step comprises lowering the pH, and wherein the treating step comprises treating the blood or blood fraction with a pharmaceutical agent that is effective in an acidic environment.

### Claim 10 (depends on 8)

The method of claim 8, wherein the modifying the environment step comprises increasing the pH of the blood or blood fraction, and wherein the treating step comprises treating the blood or blood fraction with a pharmaceutical agent that is effective in a basic environment.

### Claim 11 (depends on 8)

The method of claim 8, wherein the modifying the environment step comprises reducing the blood or blood fraction temperature to about 30° C. to about 36° C.

### Claim 12 (depends on 8)

The method of claim 8, wherein the modifying the environment step comprises increasing the blood or blood fraction temperature to about 37° C. to about 42° C.

### Claim 13 (depends on 8)

The method of claim 8, wherein the step of modifying the environment comprises adding or removing glucose to the blood or blood fraction.

### Claim 14 (depends on 8)

The method of claim 8, wherein the step of modifying the environment comprises increasing the carbon dioxide in the blood or blood fraction.

### Claim 15 (depends on 5)

The method of claim 5, wherein the treating step comprises treating the blood or blood fraction with hydrostatic pressure at a pressure range from about 50 MPa to about 1,000 MPa.

### Claim 16 (depends on 8)

The method of claim 8, wherein the step of modifying the environment comprises reducing the temperature of the blood or blood fraction, and wherein the treating step comprises treating the blood or blood fraction with hydrostatic pressure.

### Claim 17 (depends on 5)

The method of claim 5, wherein the treating step comprises treating the blood or blood fraction with a pulsed electrical field and a pharmaceutical agent.

### Claim 18 (depends on 5)

The method of claim 5, wherein the step of modifying the environment comprises reducing the blood or blood fraction temperature, and wherein the treating step comprises treating the blood or blood fraction with microwaves.

### Claim 19 (depends on 5)

The method of claim 5, further comprising a step of irradiating the blood or blood fraction after the treating step.

### Claim 20 (depends on 5)

The method of claim 5, further comprising a step of removing toxins from the blood or blood fraction after the treating step, wherein the step of removing toxins comprises filtering the blood or blood fraction, dialyzing the blood or blood fraction, chelating the blood or blood fraction, absorbing toxins from the blood or blood fraction, or a combination thereof.

### Claim 21

An extracorporeal system comprising:
a) a blood removal port;
b) an anticoagulant module;
c) a module adapted to modify the environment of blood or a blood fraction;
d) at least one treatment module adapted to administer hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, radiation, sonification, or a combination thereof; and
e) a blood return port.

### Claim 22 (depends on 21)

The extracorporeal system of claim 21, wherein the environmental module comprises at least one of a pH-modifying module, a deoxygenation module, a temperature adjustment module, a carbon dioxide module, and an osmolality module.

### Claim 23 (depends on 21)

The extracorporeal system of claim 21, wherein the environmental module is a pH-modifying module, and wherein the treatment module is adapted to administer a pharmaceutical agent that is effective at a certain pH range.

### Claim 24

A method for developing a new drug or treatment regimen in an extracorporeal system for the treatment of a subject, said method comprising the steps of:
a) obtaining a blood sample that contains a known concentration of pathogens;
b) optionally separating the blood sample into a red blood cell fraction, a buffy coat fraction, a plasma fraction, or a combination thereof;
c) modifying the environment of at least a portion of the blood sample or a blood fraction;
d) treating the blood sample or blood fraction with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, radiation, sonification, or a combination thereof; and
e) determining the concentration of pathogens in the blood sample or blood fraction after the treating step, wherein the treatment is successful for the pathogen if it eliminates or reduces the concentration of the pathogens in the blood sample or blood fraction when compared to the known concentration from step a).
